ReviewThe Journal of clinical investigation2024
Pulmonary toxicity of immune checkpoint immunotherapy.
Review in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Incidence of and risk factors for immune checkpoint inhibitor-related pneumonitis in thoracic malignancies: a prospective multicenter study.The oncologist · 2026Observational
- Risks of adverse respiratory outcomes in adults with cancer over the course of survivorship compared with cancer-free individuals: a matched cohort study using linked English electronic health records.EClinicalMedicine · 2026Article
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- Review
- Pathogen distribution characteristics and risk factors of pulmonary infection associated with immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer: a case control study.BMC infectious diseases · 2026Article
- Predictive value of combined inflammatory and coagulation markers for immune-related pneumonitis in non-small cell lung cancer patients on immunotherapy: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Etiologies and Outcomes of Acute Respiratory Failure in Patients Treated with Immune Checkpoint Inhibitors.Research square · 2026Article
- Self-reinforcing nanoplatform uniting pemetrexed, magnetic hyperthermia and PD-L1 blockade reshapes the tumor microenvironment and elicits combined antitumor immunity in lung adenocarcinoma.Materials today. Bio · 2026Article
- Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026Review
- Precise regulation of cancer vaccine and immune checkpoint inhibitor synergy potentiates immunotherapy with reduced immune-related pneumonitis.Materials today. Bio · 2026Article
- Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC.Diagnostics (Basel, Switzerland) · 2026Article
- When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management.Pulmonary therapy · 2026Review
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework.Therapeutic advances in medical oncology · 2026Review
- Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?Frontiers in immunology · 2026Observational
- Targeted Co-Delivery of Curcumin and Astragaloside IV via Hybrid Membrane-Coated Biomimetic Liposomes for Enhanced Lung Cancer Therapy.International journal of nanomedicine · 2026Article
- Drug-Induced Interstitial Lung Disease in Lung Cancer Patients.Respiration; international review of thoracic diseases · 2026Review
- Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis.Cancer communications (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of mortality on a global scale. Lung cancer, specifically non-small cell lung cancer (NSCLC), is a prominent contributor to this burden. The management of NSCLC has advanced substantially in recent years, with immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), leading to improved patient outcomes. Although generally well tolerated, the administration of ICIs can result in unique side effects known as immune-related adverse events (irAEs). The occurrence of irAEs involving the lungs, specifically checkpoint inhibitor pneumonitis (CIP), can have a profound effect on both future therapy options and overall survival. Despite CIP being one of the more common serious irAEs, limited treatment options are currently available, in part due to a lack of understanding of the underlying mechanisms involved in its development. In this Review, we aim to provide an overview of the epidemiology and clinical characteristics of CIP, followed by an examination of the emerging literature on the pathobiology of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.